The efficacy of median TAS2R14 and TAS1R1 expression in predicting survival was assessed (with TAS2R14 in adrenocortical carcinoma performing best), but additional biomarker development is necessary to determine if combinations of various TAS1R/TAS2R expression levels and additional clinical variables may allow for improved sensitivity and specificity. This evidence concerns the gene TAS1R1 and adrenal cortex carcinoma.